PTC Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 1K
- Market Cap
- $2.7B
- Website
- http://www.ptcbio.com
- Introduction
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
A Study of CNSA-001 in Women With Diabetic Gastroparesis
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT03712124
- Locations
- 🇺🇸
GW Research, Inc., Chula Vista, California, United States
🇺🇸LMG Research, Miami, Florida, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03648827
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸University of California, Los Angeles (UCLA), Los Angeles, California, United States
A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- PTC Therapeutics
- Registration Number
- NCT03642145
A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT03519711
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Utah Hospital, Salt Lake City, Utah, United States
Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 360
- Registration Number
- NCT03179631
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇦🇺Queensland Children's Hospital, South Brisbane, Australia
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT02819557
- Locations
- 🇺🇸
Children's Medical Center Dallas, Dallas, Texas, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Study of Ataluren in Participants With Nonsense Mutation Aniridia
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT02647359
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
🇺🇸Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States
Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
- Conditions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- PTC Therapeutics
- Registration Number
- NCT02592941
- Locations
- 🇺🇸
UCLA Health, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta- Scottish Rite, Atlanta, Georgia, United States
🇺🇸Children's Medical Center, Dallas, Texas, United States
Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02485431
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT02460679
- Locations
- 🇺🇸
Cedar's Sinai, Los Angeles, California, United States
🇺🇸Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States